Trasylol aprotinin injection by Bayer Logo
Link to Trasylol Home page Link to Fact Sheets page Link to Product Info page Opens Prescribing Info PDF File in new window Link to Meetings Symposia Page Link to Grants page Link to Related Sites Page link to Press Release page

Roll over the image for more information about bypass-induced SIRS.
Then click to see how TRASYLOL can help break the chain.
 


Mechanism of action does not necessarily imply clinical efficacy.

  1. Trasylol Prescribing Information.
  2. Royston D. Preventing the inflammatory response to open-heart surgery: the role of aprotinin and other protease inhibitors. Int J Cardiol. 1996; 53(suppl):S11-S37.
  3. Dietrich W. Reducing thrombin formation during cardiopulmonary bypass: is there a benefit of the additional anticoagulant action of aprotinin? J Cardiovasc Pharm. 1996;27(suppl 1): S50-S57.
  4. Royston D. full-dose aprotinin therapy: a review of the first five years' experience. J Cardiothorac Vasc Anesth. 1992; 6:76-100.
  5. Hunt BJ. Modifying perioperative blood loss. Blood Reviews. 1991;5:168-176.
  6. Royston D. Serine protease inhibition prevents both cellular and humoral responses to cardiopulmonary bypass. J Cardiovasc Pharm. 1996;27(suppl 1):S42-S49.
  7. Francis J. Effects of aprotinin on white cells and hemostasis. In: Pifarr6 R, ed. Blood Conservation With Aprotinin. Philadelphia, Pa~ Hanley & Belfus, Inc; 1995:199-214.
  8. Blauhut B, Gross C, Necek S, Doran JE, SpAth P, LUndsgaard-Hansen P. Effects of full-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1991;101:958-967.
  9. Wachtfogel YT, Kucich U, Hack CE, at al. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg. 1993;106:1-10.
  10. Wildevuur CRH, Eijsman L, Hernker HC. Aprotinin and hemostasis in cardiopulmonary bypass. In: Pifarré R, ed. Blood Conservation With Aprotinin. Philadelphia, Pa: Hanley & Belfus, Inc; 1995:227-237.
  11. Whitten CW, Latson TW, Allison PM, et al. Does aprotinin inhibit cardiopulmonary bypassinduced inflammation? Anesthesiology. 1992;77(3A):A266. Abstract.
  12. Matsuda Y, Kawata S, Nagase T, at al. Interieukin-6 in transcatheter arterial embolization for patients with hepatocellular carcinoma: effects of serine protease inhibitor. Cancer 1994;73:53-57.
  13. Welbourn CRB, Goldman G, Paterson IS, Valeri CR, Shepro D, Hechtman HB. Neutrophil elastase and oxygen radicals: synergism in lung injury after hindlimb ischernia. Am J Physiol. 1991;260:H1 852-H1 856.
  14. Primack C, Walenga JM, Koza MJ, Shankey TV, Pifarré R. Aprotinin modulation of platelet activation in patients undergoing cardiopulmonary bypass operations. Ann Thorac Surg. 1996;61:1188-1193.
  15. Himmelfarb J, Holbrook D, McMonagle E. Effects of aprotinin on complement and granulocyte activation during ex vivo hemodialysis. Am J Kidney Dis. 1994;24:901-906.
  16. van Oeveren W, Harder MP, Roozendaal KJ, Eijsman L, Wildevuur CRH. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1990;99:788-797.
  17. Data on file, Bayer Pharmaceuticals Corporation.

 


For Trasylol® contraindications, warnings and precautions see prescribing information file.

Trasylol® administration may cause fatal anaphylactic or anaphylactoid reactions. Fatal reactions have occurred with an initial (test) dose as well as with any of the components of the dose regimen. Fatal reactions have also occurred in situations where the initial (test) dose was tolerated. The risk for anaphylactic or anaphylactoid reactions is increased among patients with prior aprotinin exposure and a history of any prior aprotinin exposure must be sought prior to Trasylol® administration. The risk for a fatal reaction appears to be greater upon re-exposure within 12 months of the most recent prior aprotinin exposure. Trasylol® should be administered only in operative settings where cardio-pulmonary bypass can be rapidly initiated. The benefit of Trasylol® to patients undergoing primary CABG surgery should be weighed against the risk of anaphylaxis associated with any subsequent exposure to aprotinin.

(See CONTRAINDICATIONS, WARNINGS and PRECAUTIONS in the prescribing information.)

The information provided on Bayer products is only intended for the United States audience. Regulatory requirements, regulations, laws, and distribution of information about drug products may vary from country to country. Product names and indications (product uses) also may be different in different countries. The prescribing information provided here is based on United States labeling and may not be appropriate outside of the United States.

Top of Page | Contact Us

Home | Product Info | Prescribing Info | Meetings/Symposia | Grants | Related Sites

Copyright © Bayer Pharmaceuticals Corporation

Bayer Logo

 

Link to Bayer USA Home Page Link to Trasylol Contact Page Link to Trasylol Prescribing Info PDF